Lansoprazol Biofarmoz

Lansoprazole, the active ingredient in Lansoprazol Biofarmoz, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is used to treat acid‑related disorders such as gastro‑esophageal reflux disease, peptic ulcer disease, and erosive esophagitis in adult patients.

GNH USA supplies Lansoprazol Biofarmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazol Biofarmoz, a proton pump inhibitor, acts on the gastric acid secretion pathway to manage several acid‑related conditions. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: supports ulcer healing by decreasing gastric acidity. - Helicobacter pylori eradication: used in combination therapy to improve eradication rates. - Erosive esophagitis: aids mucosal healing by reducing acid exposure.

Lansoprazol Biofarmoz may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: kidney inflammation causing reduced urine output. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Liver enzyme elevation: potential hepatotoxicity indicated by abnormal labs. - Bone fracture risk: long‑term use may be linked to decreased bone density.

Before initiating therapy with Lansoprazol Biofarmoz, consider the following precautions. - Assess renal function: adjust use in patients with severe kidney impairment. - Evaluate hepatic status: monitor liver enzymes in those with liver disease. - Long‑term therapy: limit duration when possible to reduce fracture risk. - Concomitant medications: review for potential interactions, especially with drugs requiring acidic pH for absorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Lansoprazol Biofarmoz can affect the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption leading to therapeutic failure. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: diminished activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: may raise serum levels, necessitating dose adjustment. - Methotrexate (high dose): risk of toxicity due to reduced renal clearance. - Diazepam: may increase plasma concentrations, watch for enhanced sedation.